Patient - PACT

New Clinical Trial and Research

Trial title	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis
Trial synopsis	Participant will be required to attend approximately 10 clinic visits over approximately an 8-month period. During the 26 weeks of study treatment, participants will receive either study drug or placebo in the form of oral tablets twice a day. After a Screening visit and eligibility confirmation, participants will attend monthly clinic visits for study procedures and check-ups with their study doctor and study coordinator. At the end of this initial study treatment period, participants will be offered the option of another 26 weeks of study treatment extension. Further information on this trial can be found at **BMS Study Connect**.
Investigational medicinal product	BMS-986278 / Placebo
Disease target	Idiopathic pulmonary fibrosis and Progressive fibrotic interstitial lung disease
Sponsor	Bristol-Myers Squibb
Duration	Approximately 34 weeks, with the option of another 26 weeks of study treatment extension.
Trial Status	IPF cohort closed; PF-ILD cohort recruiting
Lead site(s) in Australia	Royal Adelaide Hospital, SA
Lead site(s) in New Zealand	No sites in New Zealand
Additional sites	• Austin Hospital, Heidelberg VIC • Westmead Hospital, Westmead NSW • Institute of Respiratory Health, Nedlands WA • Royal Prince Alfred Hospital, Camperdown NSW
Contact	pactcoordinator@cre-pf.org.au